Cargando…

Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors

BACKGROUND: Camptocormia is common in patients with multiple system atrophy (MSA). The current study was aimed at assessing the frequency of camptocormia and its related factors in MSA patients with different disease durations. Also, the impact of camptocormia on disability was evaluated. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ling Yu, Cao, Bei, Wei, Qian-Qian, Ou, Ru Wei, Zhao, Bi, Yang, Jing, Wu, Ying, Shang, Hui Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080355/
https://www.ncbi.nlm.nih.gov/pubmed/33910524
http://dx.doi.org/10.1186/s12883-021-02210-y
_version_ 1783685406814896128
author Zhang, Ling Yu
Cao, Bei
Wei, Qian-Qian
Ou, Ru Wei
Zhao, Bi
Yang, Jing
Wu, Ying
Shang, Hui Fang
author_facet Zhang, Ling Yu
Cao, Bei
Wei, Qian-Qian
Ou, Ru Wei
Zhao, Bi
Yang, Jing
Wu, Ying
Shang, Hui Fang
author_sort Zhang, Ling Yu
collection PubMed
description BACKGROUND: Camptocormia is common in patients with multiple system atrophy (MSA). The current study was aimed at assessing the frequency of camptocormia and its related factors in MSA patients with different disease durations. Also, the impact of camptocormia on disability was evaluated. METHODS: A total of 716 patients were enrolled in the study. They were classified into three groups based on disease duration (≤ 3, 3–5, ≥ 5 years). Specific scales were used to evaluate the motor and non-motor symptoms. Disease severity was assessed using the Unified Multiple System Atrophy Rating Scale (UMSARS). The binary logistic regression model was used to explore the factors related to camptocormia. To analyze the impact of camptocormia on disability in patients with disease duration less than 5 years, propensity score matching (PSM) and stratified Cox regression analysis were used. RESULTS: In the current study, we found that the frequency of camptocormia was 8.9, 19.7 and 19.2% when the disease duration was ≤3, 3–5, ≥ 5 years, respectively. In the disease duration ≤3 years group, we found that MSA-parkinsonian subtype (MSA-P) (OR = 2.043, P = 0.043), higher total UMSARS score (OR = 1.063, P < 0.001), older age of onset (OR = 1.047, P = 0.042), and lower score on the frontal assessment battery (FAB) (OR = 0.899, P = 0.046) were associated with camptocormia. Only greater disease severity was associated with camptocormia in the group of patients with disease duration 3–5 years (OR = 1.494, P = 0.025) and in the group of patients with disease duration ≥5 years (OR = 1.076, P = 0.005). There was no significant impact of camptocormia on disability in patients with a disease duration of < 5 years (HR = 0.687, P = 0.463). CONCLUSION: The frequency of camptocormia increased with prolonged disease duration. Disease severity was related to camptocormia at different stages of the disease. The MSA-P subtype, older age of onset, and lower FAB score were associated with camptocormia in the early stage of the disease.
format Online
Article
Text
id pubmed-8080355
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80803552021-04-29 Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors Zhang, Ling Yu Cao, Bei Wei, Qian-Qian Ou, Ru Wei Zhao, Bi Yang, Jing Wu, Ying Shang, Hui Fang BMC Neurol Research BACKGROUND: Camptocormia is common in patients with multiple system atrophy (MSA). The current study was aimed at assessing the frequency of camptocormia and its related factors in MSA patients with different disease durations. Also, the impact of camptocormia on disability was evaluated. METHODS: A total of 716 patients were enrolled in the study. They were classified into three groups based on disease duration (≤ 3, 3–5, ≥ 5 years). Specific scales were used to evaluate the motor and non-motor symptoms. Disease severity was assessed using the Unified Multiple System Atrophy Rating Scale (UMSARS). The binary logistic regression model was used to explore the factors related to camptocormia. To analyze the impact of camptocormia on disability in patients with disease duration less than 5 years, propensity score matching (PSM) and stratified Cox regression analysis were used. RESULTS: In the current study, we found that the frequency of camptocormia was 8.9, 19.7 and 19.2% when the disease duration was ≤3, 3–5, ≥ 5 years, respectively. In the disease duration ≤3 years group, we found that MSA-parkinsonian subtype (MSA-P) (OR = 2.043, P = 0.043), higher total UMSARS score (OR = 1.063, P < 0.001), older age of onset (OR = 1.047, P = 0.042), and lower score on the frontal assessment battery (FAB) (OR = 0.899, P = 0.046) were associated with camptocormia. Only greater disease severity was associated with camptocormia in the group of patients with disease duration 3–5 years (OR = 1.494, P = 0.025) and in the group of patients with disease duration ≥5 years (OR = 1.076, P = 0.005). There was no significant impact of camptocormia on disability in patients with a disease duration of < 5 years (HR = 0.687, P = 0.463). CONCLUSION: The frequency of camptocormia increased with prolonged disease duration. Disease severity was related to camptocormia at different stages of the disease. The MSA-P subtype, older age of onset, and lower FAB score were associated with camptocormia in the early stage of the disease. BioMed Central 2021-04-28 /pmc/articles/PMC8080355/ /pubmed/33910524 http://dx.doi.org/10.1186/s12883-021-02210-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Ling Yu
Cao, Bei
Wei, Qian-Qian
Ou, Ru Wei
Zhao, Bi
Yang, Jing
Wu, Ying
Shang, Hui Fang
Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
title Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
title_full Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
title_fullStr Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
title_full_unstemmed Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
title_short Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
title_sort camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080355/
https://www.ncbi.nlm.nih.gov/pubmed/33910524
http://dx.doi.org/10.1186/s12883-021-02210-y
work_keys_str_mv AT zhanglingyu camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT caobei camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT weiqianqian camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT ouruwei camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT zhaobi camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT yangjing camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT wuying camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors
AT shanghuifang camptocormiainpatientswithmultiplesystematrophyatdifferentdiseasedurationsfrequencyandrelatedfactors